Clicky

Morphic Holding, Inc. (MORF)

Description: Morphic Holding, Inc., a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease. Its product candidates in discovery stage include an avb1 integrin for the treatment of fibrosis; two TGF-b activations for gastrointestinal cancers and fibrosis; and other aI domain integrins. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.


Keywords: Biopharmaceutical Molecular Biology Clinical Development Gastrointestinal Inflammatory Bowel Disease Fibrosis Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Treatment Of Inflammatory Bowel Disease Gastrointestinal Cancer Treatment Of Fibrosis Gastrointestinal Cancers Integrin

Home Page: www.morphictx.com

MORF Technical Analysis

35 Gatehouse Drive, A2
Waltham, MA 02451
United States
Phone: 781 996 0955


Officers

Name Title
Dr. Praveen P. Tipirneni M.D. CEO, MD & Director
Dr. Bruce N. Rogers Ph.D. Pres
Dr. Timothy A. Springer Ph.D. Founder, Independent Director & Member of Scientific Advisory Board
Dr. Marc Schegerin M.B.A., M.D. CFO & COO
Mr. William D. DeVaul Esq. Gen. Counsel & Sec.
Mr. Robert E. Farrell Jr., CPA, CPA Sr. VP of Fin. & Operations and Chief Accounting Officer
Dr. Blaise Lippa Ph.D. Chief Scientific Officer
Mr. Aaron Pelta Sr. VP of Bus. & Corp. Devel.
Ms. Joanne Gibbons Sr. VP of Regulatory Affairs

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

GIC Sector: Health Care
GIC Group: Pharmaceuticals, Biotechnology & Life Sciences
GIC Industry: Biotechnology
GIC Sub-Industry:
Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.901
Price-to-Sales TTM: 14.0334
IPO Date: 2019-06-27
Fiscal Year End: December
Full Time Employees: 103
Back to stocks